You may have told it before, but what is your dosing regimen?
1 Like
Hi Beth, glad about you benefit from SS 31, maybe can you share your source?
1 Like
@Ulf I inject aprox 4mg many days per week.
@Paiva there are a few sources out there, but I get mine from PGB. Their stuff goes through two rounds of testing, so I feel it’s reasonably safe. Also, I have not found a better price, as long as you spend over $300 to get free shipping… normally $30. You need to know how to use crypto for their site.
I have since found someone who takes Zelle and still has a reasonable price, even if not as good. I have not bought this from him, but it’s nice to have in my back pocket. Happy to share his name in PM
Thanks, Beth. Could you share how long time it took for you to notice the positive effects
1 Like
You won’t feel any positive effects take it from me, but supposedly helps with Mitochondria which basically means while you won’t feel anything it is “supposedly” doing something. Apparently according to Attia only people with a severe condition will be able to tell some positive effects.
As per Beth, she’s claiming that her ADD has improved but that is a HUGE ? as the ADD fluctuates daily depending on even your diet, sleep quality and many, many other factors. Could it be true that SS31 has improved her ADD symptoms? Barring the usual and very common (especially in the peptide crowd) placebo effect I’d give it a 10% chance max that it is SS31 doing the heavy lifting for her ADD improvements. So, if you are looking for concrete identifiable benefits you will not be getting any. If you want to take it because you happen to believe it might help with something down the road then go right ahead and take it. To be fair most people don’t feel anything on RAPA either, yet we continue taking it. so, it is up to you.
1 Like
I plan on making an eight-week trial of SS-31. Yet to decide whether 20 mg per day for two weeks and 10 mg six weeks, or 20 mg the whole time. I bet on the dose and time being enough for a potential non-permanent remodeling of impaired mitochondria, rather than only a transient ATP spike. 6-10 weeks is a common interval in the animal studies. .
Even if mitochondria are restored, myself feeling something is highly uncertain, as Kalman writes. Before and after I will test my VO2 max + lactate; I understand lactate to be the single most sensitive and accessible metric for mitochondrial function, especially the lactate–power relationship, not just VO₂max itself. Supplemented by tests for knee extensor strength, which is a good cross sectional correlate of mitochondrial function.
Cost is high and benefit is uncertain but IMO it´s worth an attempt to beat mitochondrial decay without which our longevity efforts are weakened.
I will continue ergothioneine, and may cautiously start intranasal Orexin-A. How Mitochondrial Decline and Inflammation Drive Age-Related Fatigue
1 Like
Keep us posted on how it goes. I agree the benefits (if true) would be VERY important, while there seems to be few or no risks (other than losing weight via a way thinner wallet in your pocket LOL) to speak of.
If I were to do an experiment, I’d personally go with 20mg per day for the whole 6-10 weeks because from what I’ve read the benefits seem to only kick in at higher doses. Just my opinion, but please let us know when you’re done with your experiment. I’m very interested in finding a/some substances that help with mitochondria and if SS31 is it, I’d definitely do it every year or every other year.
1 Like
I agree, and want to carry this reasoning further. 40 mg/day is more likely to reach the exposure actually studied in humans. And some short-term treatments for acute effects only had impact at the highest dose which tended to be 35 mg per day IV = 40 mg subQ.
The reason given for lower doses for biohackers is that 40 mg/d is used for severe diseases and that a lower dose should suffice for healthy users, which to me isn´t obvious. Placing a high premium on reducing the risk of dosing too low, I am inclined towards 40 mg for 12 weeks assuming I can get hold of this amount; human trials with 40 mg/d have used 4, 12, 24, and 36‑weeks, with extensions beyond that in some cohorts.
1 Like
Sorry this is so late, I had not been around for a couple of days.
I don’t remember exactly and would have to go re-read my old posts to figure out the timeline, but if I recall, the following is more or less what happened….
Re my ADD, I’ve always had random short little bouts of great focus and ability to get things done. I say this because when I had good days early on after taking ss-31, it was nothing for me to even think about because having some high focus/motivation days are normal for me, so it would not have triggered me to pay attention to the day it began in relation to my starting dose.
Because of this, I can’t say how long it took to get symptom relief because there was no reason for me to notice anything that was not unusual for me.
At some point after starting ss-31, maybe 3 weeks-ish, I said hmmm, this seems odd… I’ve had many more good days in a row that I remember having. I was getting so much done that even my husband asked what had gotten into me. I then tried to figure out what was new in my routine which led to me asking AI if ss-31 might help with the symptoms of ADD. @John_Hemming also shared ADD might be related to mitochondria. I had zero idea about the ADD/mitochondria connection or that ss-31 could potentially help.
Can we have placebo effects if we didn’t know or even hope something might help? That seems unlikely to me, but I’m sure others here know the real answer.
Fwiw, I’m perfectly happy if this is placebo… the effect is real, so I don’t really care what the cause is.
1 Like
Wonderful to hear, Beth. Amazing results, placebo or not, from just 4 mg/d.
Logistical reasons make me go for 20 not 40 mg/d, It will be an adventure to see if any effects from SS-31 kick in. If something shows strongly in my lactate test it is likely not placebo. Time will tell…
1 Like
100mg SS-31 finally hits the research space for those wanting the higher daily doses.
https://verify.janoshik.com/tests/136644-SS31_100mg_utherpeptidecom_7MPLPHA3U3T9
4 Likes
I found out the100mg is $450.
I’m currently paying $215 for 26mg.
My source does an additional round of testing which is enough for me, but if buying from this other source it would make sense to pay for private testing.
The issue is even though Uther would still be the better deal, I’m not sure it’s enough of a savings to bother. That leads me to ……
I’ve never done a group buy and don’t know how it works, but if there are others who would want to buy this together, the cost of testing becomes insignificant.
We could buy multiple kits or share a kit… open to ideas.
I don’t currently need any, but I’m happy to stock up whenever it makes sense to do so.
At 5mg per day, mixed with 3ml of water, it would be 15 units for 20 days. I have used reconstituted glp1s for longer, so that feels perfectly fine to me.
Just chime in if anything ever wants to consider something like this.
1 Like
one vial or 10?
100mg per vial… a kit of those which is 10 vials.
1 Like
Do a group test, you don’t want the headache of a group buy. There are a number of testing groups for Uther products, so it shouldn’t be too hard to find people that want to test. Use the telegram/discord group.
1 kit.
2 Likes
Foreign concept to me. I am on telegram and discord, but I don’t know how to go about group testing. If it’s easy to explain, I’d love to learn.
If people are willing to pay me upfront, I am also fine with dealing with the group buy… they’d have to trust me though 
Yes, if you’re interested in leading one, I’ll send you a document from STG. It’s not too complicated.
2 Likes
Press release from Stealth Biotechnologies:
Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a commercial-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today provided an update on the early commercial demand for FORZINITY and highlighted continued progress across its clinical and research pipeline.
“We are encouraged that the strong early momentum of the FORZINITY launch is facilitating prompt access for patients living with Barth syndrome,” said Reenie McCarthy, Chief Executive Officer of Stealth BioTherapeutics. “We continue to advance our pipeline in rare and age-related diseases of mitochondrial dysfunction, including dry age-related macular degeneration, positioning Stealth at the forefront of the emerging therapeutic modality of mitochondrial medicine.”
Commercial Update
FORZINITY is currently commercially available for eligible U.S. patients weighing at least 30kg who are living with Barth syndrome (BTHS), a rare, serious, and life-threatening mitochondrial disease, with early launch performance demonstrating strong uptake and efficient patient onboarding to therapy.
- 33 patients have initiated therapy with 85% of patients fully covered, reflecting meaningful early adoption across treatment centers.
- Across the payer universe, we are seeing broad reimbursement access and strong coverage.
- Average time to therapy initiation is less than 30 days, from start form submission to prescription fulfillment, highlighting effective coordination across access channels.
- The Mito Assist™ patient support program has been broadly adopted, with 100% of eligible patients with FORZINITY prescriptions enrolled, providing support throughout the treatment journey.
- The Company’s field medical team deployed in early April, and the sales team, with extensive pharma and biotech experience including rare disease, will launch in early May.
- Medical and commercial organization buildout is nearing completion, including hiring across sales, market access, and promotional functions to support continued launch execution.
Research & Development Update
In parallel with commercial execution, the Company continues to advance its development of elamipretide and other mitochondria-targeted pipeline compounds for diseases of mitochondrial dysfunction.
- BTHS. The Company met and aligned with the U.S. Food and Drug Administration (FDA) on a pathway toward potential label expansion for individuals living with BTHS who do not currently meet the approved weight threshold for FORZINITY. This entails a 1-month pharmacokinetic study to inform dosing for children weighing less than 30 kilograms, which the Company plans to initiate this year to inform a potential 2027 sNDA submission for children as young as age 5. For infants and younger children, the FDA encouraged continued provision of access through the Company’s expanded access program (EAP), with a plan to initiate a registry to standardize data collection to better inform FDA review. The Company has initiated the first site in its Phase 4 trial, which is in Bristol, UK, and is meeting all FDA-required post-marketing commitments to further confirm clinical benefit.
- POLG-related myopathy. The Company had a constructive engagement with the FDA in mid-April 2026 to discuss the regulatory pathway for elamipretide in mitochondrial myopathy due to polymerase gamma (POLG) mutations. At the FDA’s request, the Company will submit a synopsis for its proposed new pivotal trial for further discussion with FDA during the second half of the year.
- Dry AMD. The Company’s Phase 3 ReNEW clinical trial of elamipretide for dry age-related macular degeneration (AMD) remains on track, with recent FDA guidance for drug development supporting the potential for a single trial to serve as the basis for approval. The Company has also completed enrollment in its Phase 1 trial of bevemipretide eye drops, with preliminary data expected at the 2026 ARVO Annual Meeting and Phase 2 initiation planned for late 2026.
- Pipeline. The Company continues to advance its broader pipeline of investigational mitochondria-targeted therapies, including participation in the XPRIZE Healthspan competition evaluating elamipretide in age-related functional decline, ongoing scientific presentations in aging research, and newly funded preclinical work on SBT-589 in Leigh syndrome through a collaboration supported by the UK Medical Research Council.
3 Likes
Hello Beth, I am good for at least two kits!
Thank you. Cheers
1 Like
Excellent! Let’s see if we get some others who are interested. I’m learning about additional testing in PMs, so hopefully we get enough people to make the test very affordable.
1 Like